Abstract:Objective: Mitochondrial damage contributes to extracellular matrix (ECM) deposition and renal fibrosis. In this study, we aimed (1) to investigate whether fluorofenidone (AKF-PD) can attenuate mitochondrial damage in two renal fibrosis models: unilateral ureteral obstruction (UUO) and renal ischemia-reperfusion injury (IRI), and (2) to explore the underlying mechanism. Method: Mitochondrial damage and renal lesions were analyzed in the UUO and IRI models. Mitochondrial energy metabolism, mitochondrial biogenesis, and oxidative stress were measured to assess the effect of AKF-PD on mitochondrial damage and to explore the underlying mechanism. In addition, HK-2 cells were stimulated with TGF-β with and without AKF-PD. The mitochondrial morphology, mtROS, ATP contents, and redox-related proteins were then examined. Results: In both UUO and IRI models, AKF-PD relieved renal fibrosis, maintained mitochondrial structure, and increased mitochondrial DNA copy numbers. The protection was associated with (1) sustaining mitochondrial energy metabolism, evident by elevations of tricarboxylic acid (TCA) cycle enzymes and mitochondrial respiratory chain complexes; (2) improving mitochondrial biogenesis with increases of TFAM, NRF1, PGC-1α, and SIRT1; and (3) reducing mitochondrial oxidative stress likely via regulating SOD2, SIRT3, and NOX4 expressions. In HK-2 cells treated with TGF-β, AKF-PD protected mitochondria along with improving mitochondrial morphology, enhancing ATP production, reducing mtROS, and regulating SOD2, SIRT3, and NOX4 expression. Conclusion: We demonstrate that AKF-PD inhibited renal fibrosis at least in part via protecting mitochondria from damages developed in the UUO and IRI models. The mitochondrial protection was associated with sustaining mitochondrial energy metabolism, improving mitochondrial biogenesis, and reducing mitochondrial oxidative stress. This research verified the protective effect of AKF-PD on mitochondria in the UUO and IRI models and elaborated the underlying mechanism.

The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy

Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction.

Fluorofenidone Attenuates Inflammation by Inhibiting the NF-кB Pathway.

Fluorofenidone Inhibits TGF-beta1 Induced CTGF Via MAPK Pathways in Mouse Mesangial Cells.

Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway

Fluorofenidone protects against renal fibrosis by inhibiting STAT3 tyrosine phosphorylation

Fluorofenidone Attenuates Renal Interstitial Fibrosis by Enhancing Autophagy and Retaining Mitochondrial Function

Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage

Fluorofenidone attenuates interleukin-1β production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction.

[Effect of Fluorofenidone on Renal Interstitial Fibrosis in Rats with Unilateral Ureteral Obstruction].

Fluorofenidone Inhibits Nicotinamide Adeninedinucleotide Phosphate Oxidase Via PI3K/Akt Pathway in the Pathogenesis of Renal Interstitial Fibrosis

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation

Fluorofenidone Attenuates Oxidative Stress and Renal Fibrosis in Obstructive Nephropathy Via Blocking NOX2 (gp91phox) Expression and Inhibiting ERK/MAPK Signaling Pathway

Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy

Fluorofenidone Inhibits Macrophage IL-1β Production by Suppressing Inflammasome Activity

Fluorofenidone Attenuates Collagen I and Transforming Growth Factor‐β1 Expression Through a Nicotinamide Adenine Dinucleotide Phosphate Oxidase‐dependent Way in NRK‐52E Cells

[Effect and mechanism of fluorofenidone on organ fibrosis].

NMDA Receptor-mediated CaMKII/ERK Activation Contributes to Renal Fibrosis